Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
1985-12-30
|
| pubmed:abstractText |
A previous randomized controlled study has shown a 30% rate of HBe antigen/antibody seroconversion within 1 year of a month course of adenine arabinoside-5'-monophosphate; no seroconversion occurred in the control group. In this study of patients derived from the same population, 45 hepatitis B virus carriers with chronic liver disease were randomized to receive either a short (4-week) course of adenine arabinoside-5'-monophosphate, a long (7 to 8-week) course of adenine arabinoside-5'-monophosphate or a 12-week course of lymphoblastoid interferon. Long-lasting suppression of hepatitis B virus replication with disappearance of serum hepatitis B virus DNA and clearance of HBeAg occurred within 12 months of treatment in four patients who received the short course of adenine arabinoside-5'-monophosphate and in five who received interferon. Of the nine responders, four also lost HBsAg. A response to antiviral therapy was accompanied by clinical and biochemical evidence of improvement in liver disease. None of the patients who received a long course of adenine arabinoside-5'-monophosphate responded. Peripheral neuropathy and myalgia were the most serious adverse effect affecting three recipients of the short course of adenine arabinoside-5'-monophosphate and eight recipients of the long course. Thrice weekly administration of interferon was well-tolerated. Further studies to identify the characteristics of the "responder patients" and large-scale controlled trials of antiviral therapy in these subgroups are indicated.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Arabinonucleotides,
http://linkedlifedata.com/resource/pubmed/chemical/Aspartate Aminotransferases,
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon Type I,
http://linkedlifedata.com/resource/pubmed/chemical/Vidarabine Phosphate
|
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0270-9139
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
5
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1132-8
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:2415436-Adult,
pubmed-meshheading:2415436-Arabinonucleotides,
pubmed-meshheading:2415436-Aspartate Aminotransferases,
pubmed-meshheading:2415436-Carrier State,
pubmed-meshheading:2415436-DNA, Viral,
pubmed-meshheading:2415436-Drug Administration Schedule,
pubmed-meshheading:2415436-Fatigue,
pubmed-meshheading:2415436-Female,
pubmed-meshheading:2415436-Fever,
pubmed-meshheading:2415436-Hepatitis B,
pubmed-meshheading:2415436-Hepatitis B virus,
pubmed-meshheading:2415436-Humans,
pubmed-meshheading:2415436-Interferon Type I,
pubmed-meshheading:2415436-Male,
pubmed-meshheading:2415436-Peripheral Nervous System Diseases,
pubmed-meshheading:2415436-Random Allocation,
pubmed-meshheading:2415436-Time Factors,
pubmed-meshheading:2415436-Vidarabine Phosphate,
pubmed-meshheading:2415436-Virus Replication
|
| pubmed:articleTitle |
A randomized study of the effects of adenine arabinoside 5'-monophosphate (short or long courses) and lymphoblastoid interferon on hepatitis B virus replication.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|